Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0000950170-24-010904

Options or other derivatives

  • Chief Executive Officer acquired 277,750 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Turtle Cameron Chief Executive Officer 2024-02-01 Grant or award · Stock Option (Right to Buy) +277,750 277,750 D: show line 1 in the form
Loading xslF345X05/ownership.xml…